July 2018
Volume 59, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2018
Development of Geographic Atrophy following Untreated Neovascular Age-related Macular Degeneration—Results from AREDS
Author Affiliations & Notes
  • Panos George Christakis
    National Eye Institute (NEI/NIH), Bethesda, Maryland, United States
  • Elvira Agron
    National Eye Institute (NEI/NIH), Bethesda, Maryland, United States
  • Michael L Klein
    Ophthalmology, Casey Eye Institute, Portland, Oregon, United States
  • J. Peter Campbell
    Ophthalmology, Casey Eye Institute, Portland, Oregon, United States
  • Frederick L Ferris
    National Eye Institute (NEI/NIH), Bethesda, Maryland, United States
  • Emily Y. Chew
    National Eye Institute (NEI/NIH), Bethesda, Maryland, United States
  • Footnotes
    Commercial Relationships   Panos Christakis, None; Elvira Agron, None; Michael Klein, None; J. Peter Campbell, Allergan (C); Frederick Ferris, None; Emily Chew, None
  • Footnotes
    Support  AREDS was supported by the National Eye Institute/National Institutes of Health, (contract no.: HHS-NOI-EY-0-2127), Bethesda Maryland.
Investigative Ophthalmology & Visual Science July 2018, Vol.59, 4947. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Panos George Christakis, Elvira Agron, Michael L Klein, J. Peter Campbell, Frederick L Ferris, Emily Y. Chew; Development of Geographic Atrophy following Untreated Neovascular Age-related Macular Degeneration—Results from AREDS. Invest. Ophthalmol. Vis. Sci. 2018;59(9):4947.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Recent studies have reported an association between anti-vascular endothelial growth factor (anti-VEGF) treatment and the development of geographic atrophy (GA) in patients with neovascular age-related macular degeneration (NV-AMD). We assessed this association by evaluating the natural history of untreated NV-AMD for the development of GA.

Methods : We used data from the Age-Related Eye Disease Study (AREDS), a long-term, multicenter, prospective clinical trial of 4757 participants with varying severity of AMD who were randomized to receive a vitamin/antioxidant and/or mineral formulation or placebo. This cohort was followed from 1992 to 2005 (median follow-up: 10.5 years), prior to the advent and FDA approval of anti-VEGF therapies for NV-AMD. Participants received standardized annual fundus photography which was graded by masked graders at a centralized reading center at the University of Wisconsin.

Results : A total of 1042 eyes developed NV-AMD during follow-up, of which 758 eyes of 664 participants did not have GA prior to NV-AMD and were eligible for analysis (Figure 1). Participants who underwent macular laser (n=325) for NV-AMD were censored at the time of treatment. Of these 758 eyes, 254 eyes developed GA within a mean of 3.1±2.6 years, corresponding to a cumulative GA risk of 54% at 8-years (Figure 2). A total of 123 eyes developed central GA within a mean of 3.3±2.5 years, corresponding to a cumulative central GA risk of 29% at 8-years. Of eyes developing GA which progressed to central GA, the majority (52%) did so within 3 years. There was no difference in the rates of development of GA after NV-AMD based on treatment group, age, sex, race, body mass index, education, or smoking status.

Conclusions : AREDS provides long-term natural history data on the largest reported cohort of participants with untreated NV-AMD. Our results demonstrate that untreated NV-AMD has a very high rate of progression to GA, and that the majority of these cases progress to involve the center of the macula. This is important to consider in the context of recent theories that anti-VEGF therapy may contribute to the development of GA.

This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.

 

Figure 1: Flowchart demonstrating the natural history of GA after untreated NV in AREDS.

Figure 1: Flowchart demonstrating the natural history of GA after untreated NV in AREDS.

 

Figure 2: Kaplan-Meier Analysis demonstrating the proportion of patients who develop GA untreated NV in AREDS.

Figure 2: Kaplan-Meier Analysis demonstrating the proportion of patients who develop GA untreated NV in AREDS.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×